Oct 10 (Reuters) - Denmark-based drugmaker Novo Nordisk NOVOb.CO said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal impairment in diabetes ... Business Wire: Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment Nasdaq: Novo Nordisk to stop Ozempic trial to treat renal impairment early Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...
This transcript has been edited for clarity. Silvio Inzucchi, MD: Welcome to Medscape InDiscussion. I'm Dr Silvio Inzucchi, and today we're talking about type 2 diabetes and our move away from glucose ... The New England Journal of Medicine: Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes The American Journal of Managed Care: Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes
